通过dupilumab和过敏免疫治疗对过敏性鼻炎鼻腔转录组的微分调节和过敏免疫治疗
Matthew F Wipperman1, Kaitlyn M Gayvert1, Amanda Atanasio1
1Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
Allergy
|January 27, 2024
概括
杜皮卢马布和组合疗法显著减少过敏性鼻炎 (AR) 基因特征,表明2型炎症是AR的关键. 杜皮卢马布可以使AR患者的鼻腔组织基因表达正常化.
科学领域:
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
- 过敏研究 研究过敏
背景情况:
- 鼻上皮细胞调节屏障功能和免疫反应.
- 过敏性鼻炎 (AR) 通过炎症媒介破坏这些功能.
- 了解AR机制需要分析鼻腔组织基因表达.
研究的目的:
- 使用转录组数据调查AR疾病机制.
- 分析鼻腔组织中的基因表达特征.
- 评估dupilumab和皮下免疫疗法 (SCIT) 对AR基因特征的影响.
主要方法:
- 来自AR和无AR个体的鼻刷样本的转录组分析.
- 评估包括dupilumab,SCIT,SCIT+dupilumab和安慰剂在内的治疗方法.
- 鉴定和对AR疾病和鼻过敏原挑战 (NAC) 基因签名的调制评估.
主要成果:
- 杜比卢马布和SCIT+杜比卢马布显著抑制了AR疾病基因特征.
- 杜比卢马布,SCIT和SCIT+杜比卢马布都抑制了NAC基因签名.
- 单独使用SCIT并没有显著抑制AR疾病特征.
结论:
- 2型炎症对AR病理生理学有显著的贡献.
- 杜皮卢马布有效地抑制了AR的2型炎症途径.
- 用dupilumab准2型炎症可能会使AR中的鼻腔组织基因表达正常化.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
298
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
298
Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442
Allergic Reactions
27.4K
Overview
27.4K
Asthma: Pathogenesis and Management
403
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
403
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K


